Skip to content
PoliticalRepoPoliticalRepo

Ireland · Question · written

PQ 267

267. Deputy David Cullinane asked the Minister for Health following the relevant NCPE recommendation, the number and dates of substantive commercial engagements between the HSE and the manufacturer of a medication (details supplied); whether the HSE sought an improved commercial offer or made or invited any counterproposal; whether and when senior HSE management became directly involved in the reimbursement or commercial process; the current status of the process; and the objective factors which have informed the HSE's approach and decisions to date, without requiring disclosure of commercially confidential net pricing, in tabular form. [70807/26]

askedIreland· Dáil Éireann· EN

Introduced

7 October 2026

Last action

7 October 2026 · Medicinal Products

Status

written

Sponsors

David Cullinane

Subjects

Discovery layer

Source updated

7 October 2026

Summary

267. Deputy David Cullinane asked the Minister for Health following the relevant NCPE recommendation, the number and dates of substantive commercial engagements between the HSE and the manufacturer of a medication (details supplied); whether the HSE sought an improved commercial offer or made or invited any counterproposal; whether and when senior HSE management became directly involved in the reimbursement or commercial process; the current status of the process; and the objective factors which have informed the HSE's approach and decisions to date, without requiring disclosure of commercially confidential net pricing, in tabular form. [70807/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 7 October 2026

    Medicinal Products

    267. Deputy David Cullinane asked the Minister for Health following the relevant NCPE recommendation, the number and dates of substantive commercial engagements between the HSE and the manufacturer of a medication (details supplied); whether the HSE sought an improved commercial offer or made or invited any counterproposal; whether and when senior HSE management became directly involved in the reimbursement or commercial process; the current status of the process; and the objective factors which have informed the HSE's approach and decisions to date, without requiring disclosure of commercially confidential net pricing, in tabular form. [70807/26]

    Source: written

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

2 official files

Medicinal Products

View fileDownload file

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Medicinal Products

    xml · EN · 7 October 2026

    ViewDownloadOpen at official source

  • Question

    text · EN · 7 October 2026

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.